Rexahn Pharmaceuticals Announces Collaboration with Zhejiang Haichang Biotechnology Co., Ltd. for the Development of RX-0201 (Archexin®) for the treatment of Hepatocellular Carcinoma
February 08, 2018 08:00 ET
|
Rexahn Pharmaceuticals
Haichang to fund development through completion of Phase IIa Proof-of-Concept Clinical Trial Clinical trials will be designed to meet both the US and China FDA requirements ROCKVILLE, Md., Feb. 08,...
Rexahn Pharmaceuticals to Present at the American Society of Clinical Oncology Genitourinary Cancers (ASCO GU) 2018 Annual Meeting
February 05, 2018 08:00 ET
|
Rexahn Pharmaceuticals
ROCKVILLE, Md., Feb. 05, 2018 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American:RNN), a clinical stage biopharmaceutical company developing next generation therapeutics for the...
Rexahn Pharmaceuticals Receives Notice of Allowance for A New U.S. Patent Covering the Use of RX-5902 (Supinoxin™)
January 29, 2018 08:00 ET
|
Rexahn Pharmaceuticals
ROCKVILLE, Md., Jan. 29, 2018 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American:RNN), a clinical stage biopharmaceutical company developing innovative, targeted therapeutics for the...
Rexahn Pharmaceuticals Announces Poster Presentation of RX-3117 Data in Metastatic Pancreatic Patients at the American Society of Clinical Oncology Gastrointestinal Cancers (ASCO GI) 2018 Annual Meeting
January 22, 2018 07:30 ET
|
Rexahn Pharmaceuticals
Encouraging Progression Free Survival and Evidence of Tumor Shrinkage Observed in Patients with Metastatic Pancreatic Cancer Resistant to Gemcitabine who had Failed on Multiple Prior Treatments ...
Rexahn Pharmaceuticals to Present at the American Society of Clinical Oncology Gastrointestinal Cancers (ASCO GI) 2018 Annual Meeting
January 18, 2018 09:00 ET
|
Rexahn Pharmaceuticals
ROCKVILLE, Md., Jan. 18, 2018 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American:RNN), a clinical stage biopharmaceutical company developing next generation therapeutics for the...
Rexahn Pharmaceuticals to Present at Biotech Showcase™ 2018
January 08, 2018 09:00 ET
|
Rexahn Pharmaceuticals
ROCKVILLE, Md., Jan. 08, 2018 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American:RNN), a clinical stage biopharmaceutical company developing next generation therapeutics for the...
Rexahn Pharmaceuticals Announces the Appointment of Douglas J. Swirsky as President and Chief Financial Officer
January 04, 2018 09:00 ET
|
Rexahn Pharmaceuticals
ROCKVILLE, Md., Jan. 04, 2018 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing innovative, targeted therapeutics for the...
Rexahn Pharmaceuticals Presents New Preclinical Data on Supinoxin™ at the 2017 San Antonio Breast Cancer Symposium
December 11, 2017 09:00 ET
|
Rexahn Pharmaceuticals
Supinoxin enhances the efficacy of immunotherapy in multiple preclinical models Supinoxin shows potent activity against patient-derived triple negative breast cancer (TNBC) tumors in preclinical...
Rexahn Pharmaceuticals to Present at the Stifel 2017 Healthcare Conference
November 09, 2017 09:00 ET
|
Rexahn Pharmaceuticals
ROCKVILLE, Md., Nov. 09, 2017 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American:RNN), a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment...
Rexahn Pharmaceuticals Doses First Patient in a Phase IIa Clinical Trial of RX-3117 in Combination with Abraxane® in Patients Newly Diagnosed with Metastatic Pancreatic Cancer
November 08, 2017 09:00 ET
|
Rexahn Pharmaceuticals
ROCKVILLE, Md., Nov. 08, 2017 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE AMERICAN:RNN), today announced that it has dosed the first patient in a Phase IIa clinical study of RX-3117 in...